She loves drawing and playing with her friends. Months ago, Audrey started experiencing abdominal pain, fever and fatigue. Her parents took her to their doctor. After multiple tests, she was diagnosed with rhabdomyosarcoma, a soft-tissue cancer. Before long Audrey started experiencing significant treatment side effects, including heart and neurologic problems, landing her in the ICU with an uncertain prognosis.
Audrey is not alone. More than 400 individuals in the US will be diagnosed with rhabdomyosarcoma in 2019, mostly children and teens. Most will experience serious side effects, like Audrey, due to treatment. Many will relapse with difficult to treat mutations.
We are here for them. We are here for Audrey.
Created in 2015, on research from world leading chemist Dr. Jindřich “Henry” Kopeček, our polymer antibody conjugate platform uses a unique mechanism of action to crosslink cell receptors, providing transformative solutions for patients, oncologists, and payers.
HOW IT WORKS
Cells Talk...A Lot.
Every cell in your body needs to communicate, to keep its neighbors up to date. Much of this communication occurs by proteins that stay on the cell's surface, cell receptors. These communication signals can be subverted when disease occurs. At Bastion, we have discovered a way to hijack these cell receptors: changing their communication to eliminate cancers, autoimmune, and neurologic diseases.
learn how receptor crosslinking is disrupting oncology
Meet the Team
Chief Scientific Advisor
World Leader in Biopolymer Chemistry
DR. PAUL SHAMI
Chief Medical Advisor
Leader in Blood Cancer Drug Development
DR. JANE YANG
Polymer & Conjugation Advisor
Polymer Scale Up Specialist
DR. DAVE HOBSON
Leader in FDA Relations
DR. DAVID NOWOTNIK
Product Development Advisor
Leader in Polymer Drug Development